文献速递脑血管病外科神经重症

高通量代谢物谱分析:血浆牛磺酸作为动脉瘤性蛛网膜下腔出血后功能结局的潜在生物标志物

High-throughput metabolite profiling: identification of plasma taurine as a potential biomarker of functional outcome after aneurysmal subarachnoid hemorrhage.
PubMed 文献 · J Neurosurg · 2019-11-22

该研究对191例动脉瘤性蛛网膜下腔出血患者(最终纳入137例)在发病后0-5、6-10、11-14天采集血浆,进行163种代谢物的高通量代谢物谱分析,采用弹性网络和LASSO机器学习筛选与90天功能结局(mRS)相关的代谢物。结果显示牛磺酸是与90天功能结局最相关的代谢物,发病0-5天血浆牛磺酸水平在结局良好组较结局不良组高21.9%(p=0.002),校正混杂因素后牛磺酸仍为功能结局的显著预测因子(p=0.013;OR 3.41,95%CI 1.28-11.4)。作者结论为动脉瘤性蛛网膜下腔出血后血浆牛磺酸升高预测90天功能结局良好,动物实验提示该效应可能通过下调促炎细胞因子介导,但需进一步研究在人体中验证该假说。

要点

  • 在137例动脉瘤性蛛网膜下腔出血患者中,79例(57.7%)90天功能结局良好(mRS评分0-2分)。
  • 弹性网络和LASSO机器学习方法识别牛磺酸为与90天功能结局最相关的代谢物(p<0.0001)。
  • 发病0-5天血浆牛磺酸水平结局良好组较结局不良组高21.9%(p=0.002),校正后仍为显著预测因子(p=0.013;OR 3.41,95%CI 1.28-11.4)。

核心结论

  • 动脉瘤性蛛网膜下腔出血后血浆牛磺酸水平升高预测90天功能结局良好。
  • 动物实验提示该效应可能通过下调促炎细胞因子介导,但需进一步研究在人体中验证该假说。

研究设计与样本

  • 对2011年5月至2016年10月期间就诊于Massachusetts General Hospital的191例蛛网膜下腔出血患者采集血浆样本,最终137例(71.7%)动脉瘤性蛛网膜下腔出血患者符合纳入标准。
  • 在发病后0-5天、6-10天、11-14天三个时间点采血,对163种代谢物进行高通量代谢物谱分析。
  • 采用弹性网络和LASSO机器学习分析识别与90天功能结局(改良Rankin量表,mRS)相关的代谢物,并进行单因素和多因素分析进一步 examine 代谢物与临床变量及90天功能结局的关系。

主要发现

  • 137例患者中79例(57.7%)90天功能结局良好(mRS评分0-2分)。
  • 结局良好组患者较结局不良组更年轻(p=0.002),入院Hunt and Hess分级更低(p<0.0001),改良Fisher分级更低(p<0.0001),且未发生脑积水(p<0.0001)或迟发性脑缺血(DCI)(p=0.049)。
  • 弹性网络和LASSO机器学习方法识别牛磺酸为与90天功能结局最相关的代谢物(p<0.0001)。
  • 发病0-5天采集样本的血浆氨基酸牛磺酸浓度,结局良好组较结局不良组高21.9%(p=0.002)。
  • 校正年龄、Hunt and Hess分级、改良Fisher分级、脑积水和DCI后,逻辑回归显示牛磺酸仍为功能结局的显著预测因子(p=0.013;OR 3.41,95%CI 1.28-11.4)。

局限性

  • 动物实验提示该效应可能通过下调促炎细胞因子介导,但需进一步研究在人体中验证该假说。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Metabolite profiling (or metabolomics) can identify candidate biomarkers for disease and potentially uncover new pathways for intervention. The goal of this study was to identify potential biomarkers of functional outcome after subarachnoid hemorrhage (SAH). METHODS: The authors performed high-throughput metabolite profiling across a broad spectrum of chemical classes (163 metabolites) on plasma samples taken from 191 patients with SAH who presented to Massachusetts General Hospital between May 2011 and October 2016. Samples were drawn at 3 time points following ictus: 0-5, 6-10, and 11-14 days. Elastic net (EN) and LASSO (least absolute shrinkage and selection operator) machine learning analyses were performed to identify metabolites associated with 90-day functional outcomes as assessed by the modified Rankin Scale (mRS). Additional univariate and multivariate analyses were then conducted to further examine the relationship between metabolites and clinical variables and 90-day functional outcomes. RESULTS: One hundred thirty-seven (71.7%) patients with aneurysmal SAH met the criteria for inclusion. A good functional outcome (mRS score 0-2) at 90 days was found in 79 (57.7%) patients. Patients with good outcomes were younger (p = 0.002), had lower admission Hunt and Hess grades (p < 0.0001) and modified Fisher grades (p < 0.0001), and did not develop hydrocephalus (p < 0.0001) or delayed cerebral ischemia (DCI) (p = 0.049). EN and LASSO machine learning methods identified taurine as the leading metabolite associated with 90-day functional outcome (p < 0.0001). Plasma concentrations of the amino acid taurine from samples collected between days 0 and 5 after aneurysmal SAH were 21.9% (p = 0.002) higher in patients with good versus poor outcomes. Logistic regression demonstrated that taurine remained a significant predictor of functional outcome (p = 0.013; OR 3.41, 95% CI 1.28-11.4), after adjusting for age, Hunt and Hess grade, modified Fisher grade, hydrocephalus, and DCI. CONCLUSIONS: Elevated plasma taurine levels following aneurysmal SAH predict a good 90-day functional outcome. While experimental evidence in animals suggests that this effect may be mediated through downregulation of pro-inflammatory cytokines, additional studies are required to validate this hypothesis in humans.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Stapleton CJ, Acharjee A, Irvine HJ, et al. High-throughput metabolite profiling: identification of plasma taurine as a potential biomarker of functional outcome after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2019. PMID: 31756713. doi:10.3171/2019.9.JNS191346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。